SEC Filing Summary: Pacific Biosciences of California, Inc. (PACB)
Business Context and Reporting Period
This Form 8-K Current Report was filed on January 24, 2025, by Pacific Biosciences of California, Inc. The report covers corporate governance events occurring on January 24, 2025, and January 29, 2025, with effective dates of January 30, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on changes to the Board of Directors and does not contain financial performance data.
Material Changes
- Appointment of Director: The Board appointed Christopher M. Smith as a Class III director, effective January 30, 2025. His initial term expires at the 2025 annual meeting of stockholders.
- Resignation of Director: David Meline notified the Company of his resignation from the Board, effective January 30, 2025.
- Reason for Resignation: The Company stated it is not aware of any disagreement between Mr. Meline and the Company regarding operations, policies, or practices that resulted in the resignation.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on business performance. Regarding risks and contingencies, the Company confirmed there are no related party transactions requiring disclosure under Item 404(a) of Regulation S-K involving Mr. Smith. Mr. Smith will participate in the standard non-employee director compensation policy and will enter into a standard indemnification agreement.
Investor Verification Checklist
- Verify the effective date of the Board composition change (January 30, 2025).
- Review the definitive proxy statement filed on April 29, 2024, for details on the non-employee director compensation policy applicable to Mr. Smith.
- Confirm the absence of any undisclosed disagreements related to Mr. Meline's departure.
- Note that no financial metrics or operational updates are included in this specific filing.